NOTE: For the first time the analyst who provided the numbers commented that TEVA has a generic near approval that will take the majority of the generic market (FWIW).
You've got to be joking... Wasn't TEVA's generic near approval more than 7 months ago? I love the "will take the majority of the generic market" part. I hope for his sake he was talking about an entirely different generic.